MAPT and Hodgkins lymphoma: In liver cancer cell lines, MAPT expression was negatively associated with resistance to bleomycin, a DNA-damaging drug approved for squamous cell head and neck cancer, Hodgkin’s lymphoma, and testicular carcinoma55.